SageView Advisory Group LLC Invests $321,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SageView Advisory Group LLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,623 shares of the medical equipment provider’s stock, valued at approximately $321,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZBH. OLD Point Trust & Financial Services N A bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $26,000. Naples Money Management LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at about $35,000. Activest Wealth Management increased its position in Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 275 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Zimmer Biomet by 48.4% in the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after buying an additional 153 shares during the period. Finally, Quent Capital LLC lifted its position in shares of Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 92 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZBH has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th. Canaccord Genuity Group restated a “hold” rating and set a $130.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 23rd. Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a report on Tuesday, May 21st. Truist Financial decreased their price target on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, May 3rd. Finally, Barclays dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $133.75.

Zimmer Biomet Trading Down 0.3 %

ZBH stock opened at $106.69 on Thursday. The firm has a market cap of $21.95 billion, a PE ratio of 23.09, a price-to-earnings-growth ratio of 1.92 and a beta of 1.02. The firm has a fifty day moving average price of $117.34 and a 200 day moving average price of $121.64. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $147.50.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the firm posted $1.89 EPS. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.